Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-center, Randomized, 2-arm Parallel, Double-blind, Active-comparator (Darbepoetin Alfa) Conversion Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia

NCT02952092 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT02952092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02952092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-center, Randomized, 2-arm Parallel, Double-blind, Active-comparator (Darbepoetin Alfa) Conversion Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia
Lead sponsor
Astellas Pharma Inc
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2016
Completion date
March 15, 2018
Enrollment
303 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

hemodialysis chronic kidney disease patients with anemia